# Junta clínica — PT-pseudo_4b950525e6a8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4b950525e6a8",
  "pid": "PT-pseudo_4b950525e6a8",
  "task": 1,
  "psa": 19.0,
  "age": 65,
  "months": 2,
  "pirads": "5",
  "psad": 0.37,
  "psav": 2.0,
  "psap": 18.4,
  "vol": 51.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.88825184,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "80 kg",
    "height": "175 cm",
    "bmi": "26.1",
    "bp": "134/81 mmHg",
    "hr": "80 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2022)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Mar 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review."
    },
    {
      "s": "History",
      "t": "A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Widowed",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 22/35 (severe LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4b950525e6a8
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.37 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 18.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.88825184 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.

Vitals: weight 80 kg, height 175 cm, BMI 26.1, BP 134/81 mmHg, HR 80 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2022).

Chief complaint: Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review.

History: A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria.

Physical examination: DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable.

Patient info: retired shopkeeper; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.51
  uncertainty  +/- 0.19 epistemic (95% band 0.14-0.87); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 65 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 19 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 51 mL (1% of my signal; from log_vol, vol) · PSA density = 0.37 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.89 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 65 · DRE = Normal · PSA = 19 ng/mL · prostate volume = 51 mL · PSA density = 0.37 · PI-RADS = 5 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.73: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."
  2. distance 0.86: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.65: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"

PRECEDENT: DEFER (weighted vote 0.43 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 65 · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · PSA = 19 ng/mL · prostate volume = 51 mL · PSA density = 0.37 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 65 · PSA = 19 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 51 mL · PSA density = 0.37 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
"linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy."
The guideline suggests using a risk-adapted matrix table based on PI-RADS score and PSA density to guide the decision to perform a biopsy. For this patient, the PI-RADS score is 5 and the PSA density is 0.37 ng/mL², which falls into the highest risk category according to the retrieved data.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline makes the PSA density level decisive, which EXPERT-STRUCTURED marked as 'not used'. The guideline suggests that a PSA density of 0.37 ng/mL² places the patient in the highest risk category, which the guideline makes decisive. The guideline requires the prior grade of the prior biopsy to be established, which EXPERT-COHORT marked as 'decisive'. The guideline requires a comparison MRI or a due confirmatory biopsy, which EXPERT-TRACE marked as 'important'.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trajectory: the trend is not explicitly detailed in the provided data, so the guideline does not provide a specific instruction based on it.
laboratory_results - the PSA density: the guideline makes this variable decisive, and the value of 0.37 ng/mL² places the patient in the highest risk category.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on establishing the documented grade of the prior biopsy, as the EAU guideline requires this information to guide the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the radiology_report indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA trajectory?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy?
  laboratory_results (get_lab_results) -> What is the PSA density?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. Does the radiology_report indicate whether the lesion is compared against an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.

psa_trend
What is the PSA trajectory?
PSA 2.1 (Jul 2023) rising to 6.3 (May 2024), rising to 19.0 (Mar 2025), steepest in the last year.

previous_notes
What is the documented grade of the prior biopsy?
PRIOR GRADE: Gleason 4+4 carcinoma
BIOPSY SESSIONS: 1, on 04 Jul 2024
SURVEILLANCE: not recorded
TREATMENT: none recorded

laboratory_results
What is the PSA density?
PSA density 0.37 ng/mL/mL.

WHAT I DID NOT OPEN
family-history anamnesis, because the documented prior biopsy grade and imaging findings are more immediately relevant to the decision.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.
PSA density 0.37 ng/mL/mL, which falls into the highest risk category according to the EAU guideline.

AGAINST sampling this patient now
PRIOR GRADE: Gleason 4+4 carcinoma, suggesting a prior definitive diagnosis.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 19.00 ng/mL over 3 points spanning 20 months; velocity +10.14 ng/mL per year; doubling time about 6 months.
PROJECTION at 6 months: 32.3 ng/mL, conformal 95% band 9.3-112.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 19 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.35
  uncertainty  +/- 0.15 epistemic (95% band 0.06-0.64), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 19 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 51 mL (4% of my signal; from log_vol, vol) · PSA density = 0.37 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.51  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.35  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.43  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: GG 4 ("Gleason 4+4")

RULE THAT FIRED: documented prior grade GG 4 (Gleason 4+4) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          65                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          19 ng/mL                     E1:not E3:not cohort:not library:not E2:not          -> important
  vol          51 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.37                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.89                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) have answered the moderator's questions.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the panel rule fired based on the "documented prior grade GG 4 (Gleason 4+4)".

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? Answered by the registrar: PRIOR GRADE: Gleason 4+4 carcinoma.
Q2. Does the radiology_report indicate whether the lesion is compared against an earlier study? Answered by the registrar: COMPARISON: new.

WHAT CARRIES WEIGHT, AND WHY
documented prior grade: decisive: GG 4 (Gleason 4+4) because the PANEL-PROTOCOL explicitly states this rule fired, overriding other expert bids.
PSA density: noted: 0.37 ng/mL/mL because the EAU guideline made this variable decisive, placing the patient in the highest risk category.
my confidence in the record as it stands is clear because all required documents were retrieved and the panel protocol's decision is directly supported by a retrieved finding.

MY SUGGESTION TO THE CHAIR
I suggest deferral based on the PANEL-PROTOCOL, as the documented prior grade of Gleason 4+4 carcinoma is a treatment problem, not a sampling problem.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

65y male, PSA 19.0, PSAD 0.37, PI-RADS 5, prior biopsy Gleason 4+4. Given documented prior cancer, repeat biopsy is not indicated. The PI-RADS 5 finding is expected given the rising PSA and known prior diagnosis. No earlier MRI to compare with.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
